Shanghai Pharmaceuticals Holding Co Ltd (601607) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Pharmaceuticals Holding Co Ltd (601607) has a cash flow conversion efficiency ratio of 0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥1.56 Billion) by net assets (CN¥89.62 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Pharmaceuticals Holding Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Shanghai Pharmaceuticals Holding Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shanghai Pharmaceuticals Holding Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Pharmaceuticals Holding Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Terreno Realty Corporation
NYSE:TRNO
|
0.017x |
|
AAK AB
ST:AAK
|
0.014x |
|
Talkweb Information System Co Ltd
SHE:002261
|
0.178x |
|
Artemis Gold Inc
V:ARTG
|
0.196x |
|
The Phoenix Mills Limited
NSE:PHOENIXLTD
|
0.084x |
|
Terex Corporation
NYSE:TEX
|
0.098x |
|
TPG Inc
NASDAQ:TPG
|
-0.011x |
|
Shenzhen Capchem Tech
SHE:300037
|
0.033x |
Annual Cash Flow Conversion Efficiency for Shanghai Pharmaceuticals Holding Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Pharmaceuticals Holding Co Ltd from 1998 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥89.79 Billion | CN¥6.15 Billion | 0.069x | -1.50% |
| 2024-12-31 | CN¥83.74 Billion | CN¥5.83 Billion | 0.070x | +6.84% |
| 2023-12-31 | CN¥80.33 Billion | CN¥5.23 Billion | 0.065x | +7.10% |
| 2022-12-31 | CN¥78.00 Billion | CN¥4.74 Billion | 0.061x | -29.03% |
| 2021-12-31 | CN¥59.07 Billion | CN¥5.06 Billion | 0.086x | -31.47% |
| 2020-12-31 | CN¥54.74 Billion | CN¥6.84 Billion | 0.125x | +2.54% |
| 2019-12-31 | CN¥49.39 Billion | CN¥6.02 Billion | 0.122x | +80.61% |
| 2018-12-31 | CN¥46.43 Billion | CN¥3.14 Billion | 0.068x | +1.13% |
| 2017-12-31 | CN¥39.68 Billion | CN¥2.65 Billion | 0.067x | +26.32% |
| 2016-12-31 | CN¥36.83 Billion | CN¥1.95 Billion | 0.053x | +32.43% |
| 2015-12-31 | CN¥33.81 Billion | CN¥1.35 Billion | 0.040x | -7.08% |
| 2014-12-31 | CN¥31.10 Billion | CN¥1.34 Billion | 0.043x | +27.95% |
| 2013-12-31 | CN¥29.00 Billion | CN¥973.45 Million | 0.034x | -19.20% |
| 2012-12-31 | CN¥27.70 Billion | CN¥1.15 Billion | 0.042x | -39.10% |
| 2011-12-31 | CN¥25.98 Billion | CN¥1.77 Billion | 0.068x | -51.92% |
| 2010-12-31 | CN¥11.88 Billion | CN¥1.69 Billion | 0.142x | -50.39% |
| 2009-12-31 | CN¥2.32 Billion | CN¥664.13 Million | 0.286x | +109.19% |
| 2008-12-31 | CN¥2.09 Billion | CN¥285.68 Million | 0.137x | -45.25% |
| 2007-12-31 | CN¥1.96 Billion | CN¥488.94 Million | 0.250x | -11.50% |
| 2006-12-31 | CN¥2.07 Billion | CN¥583.11 Million | 0.282x | +675.17% |
| 2005-12-31 | CN¥2.01 Billion | CN¥73.00 Million | 0.036x | +21.65% |
| 2004-12-31 | CN¥2.06 Billion | CN¥61.66 Million | 0.030x | +13043.04% |
| 2003-12-31 | CN¥2.13 Billion | CN¥484.27K | 0.000x | -99.55% |
| 2002-12-31 | CN¥2.00 Billion | CN¥100.84 Million | 0.050x | +39.50% |
| 2001-12-31 | CN¥1.82 Billion | CN¥65.73 Million | 0.036x | -75.64% |
| 2000-12-31 | CN¥985.30 Million | CN¥146.22 Million | 0.148x | -23.41% |
| 1999-12-31 | CN¥849.92 Million | CN¥164.67 Million | 0.194x | +148.82% |
| 1998-12-31 | CN¥713.42 Million | CN¥-283.14 Million | -0.397x | -- |
About Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric … Read more